OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

OBB RSS Feed

  •  

Event Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2014

« Teva Wins in District Court, Launches Generic Famvir, Then is Enjoined by Federal Circuit the Next Day | Main | BIO CEO Jim Greenwood Discusses Follow-On Biologics in Conference Call With Bloggers »

September 16, 2007

Comments

Cary

This comment is directed to the subject of Ranbaxy going after the patent on Lipitor. I find it hard to believe that Pfizer is going to let the patent on the number one selling drug in the world expire 1 second early. But on the other hand, this opportunity is too big for Ranbaxy to pass up. A favorable verdict would give them exclusive rights to sell a generic version of the medicine, for a limited period, at a price that is well below Lipitor's but gives Ranbaxy a huge profit margin.

So Ranbaxy will fight, and Pfizer will win. To the deepest pockets go the spoils.

The comments to this entry are closed.